Autopsy report · NCT01704599

Addition of Modulators of Homocysteine to Adalimumab Therapy in the Treatment of Moderate to Severe Plaque Psoriasis

“side effect and poor clinical outcome”

The sponsor’s own words in the registry.

Life of this trial

• Registered 3 years 9 months after it had already started.
• Ran for about 5 years 4 months before it stopped.
• 8 participants enrolled.
• Results were posted on the registry 9 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 1, Phase 2

Sponsor

Wayne State University

Sponsor type

University, hospital or other

Conditions

Psoriasis

Interventions

Humira Then Humira plus 3 B vitamins

Participants

8

Trials that died the same way

• Study to Evaluate the Efficacy, Safety and Immunogenicity of Subcutaneous HX575 in the Treatment of Anemia Associated With Chronic Kidney Disease (SWEEP)
  “investigation of adverse events in a related clinical study” (63% match in meaning)
• Phase Ib/IIa Trial to Evaluate Oregovomab and Nivolumab in Epithelial Cancer of Ovarian, Tubal or Peritoneal Origin
  “The study had poor efficacy.” (60% match in meaning)
• In-Vivo Activated T-Cell Depletion to Prevent GVHD
  “Treatment ineffective” (57% match in meaning)
• Utility of Tocolytic Therapy for Maintenance Tocolysis in the Management of Threatened Preterm Delivery
  “have been published new studies that it showed the ineffectiveness of the treatments proposed in this study.” (56% match in meaning)
• Development of Cocktail for Measuring the Activity of Important Cytochrome P450 Enzymes
  “Unexpected non-serious adverse events” (56% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.